Group items tagged

The purpose of the Disability and Rehabilitation Research Projects and Centers Program is to plan and conduct research, demonstration projects, training, and related activities, including international activities, to develop methods, procedures, and rehabilitation technology that maximize the full inclusion and integration into society, employment, independent living, family support, and economic and social self-sufficiency of individuals with disabilities, especially individuals with the most severe disabilities, and to improve the effectiveness of services authorized under the Rehabilitation Act of 1973, as amended (Rehabilitation Act).

This funding opportunity announcement (FOA)) invites applications employing secondary analysis of existing data sets or stored biospecimens, to address clinically-related issues on aging changes influencing health across the life span, and/or on diseases and disabilities in older persons. This FOA will support activities addressing specific hypotheses in clinical aging research and/or to inform the design and implementation of future epidemiologic or human intervention studies, or current geriatric practice in maintenance of health, management of disease, and prevention of disability. Existing data sets may also be used to develop and test new statistical analytical approaches. Costs for archiving of data to be made publicly available may be included in the budget, as long as the archival activities are pertinent to the proposed secondary analyses.

The purpose of this FOA is to support an initial series of activities over a 3-year period to build the foundation for enhanced collaborations across NIA's 6 centers programs. These collaborations are intended to leverage NIA's substantial investments by fostering the development of novel interdisciplinary efforts in aging research. This opportunity will provide resources to build additional infrastructure and establish specific collaborative activities that could include, but are not limited to, information and data exchange, meetings and conferences, pilot studies, research opportunities for beginning investigators, visiting scholar programs, dissemination, and other collaborative efforts. The successful awardee will involve all 6 centers programs.

In May of 2013 the National Institute of Neurological Disorders and Stroke (NINDS), with input from the National Institute on Aging (NIA), held an Alzheimer's Disease-Related Dementias Conference in response to the National Plan to Address Alzheimer's Disease. The Conference brought together national and international experts and members of the public to develop research priorities for accelerating the development of therapies for the Alzheimer's disease-related dementias (ADRDs). The ADRD 2013 research recommendations that resulted are part of the National Plan to Address Alzheimer's Disease. This FOA addresses the National Plan's highest priority for human-based research on vascular contributions to cognitive impairment and dementia (VCID): to develop noninvasive markers of key vascular processes related to VCID in Alzheimer's and related dementias. The research program initiated here underscores the need to facilitate the development of biomarkers to improve the efficiency and outcome of Phase II and III clinical trials and advance therapeutic development. These companion FOAs (RFA-NS-16-019, i.e. this FOA; and RFA-NS-16-020 for the Biomarkers Development Projects) establish the Small Vessel VCID Biomarkers Consortium, and are focused on small vessel (i.e. arterioles, capillaries, and venules) VCID in vascular cognitive impairment (VCI), vascular dementia, and all mixed and pure cognitive impairment and dementias with contributing small vessel vascular disease, including such as commonly occurs in sporadic Alzheimer's disease. Awards funded under these two FOAs create a consortium and infrastructure to complete development projects as well as planning that will enable follow-up activities (to be carried out under future separate funding; for example large scale multi-site validation studies and other activities, for future FDA qualification of small vessel VCID biomarkers and use in clinical trials).

CAREER: The Faculty Early Career Development (CAREER) Program is a Foundation-wide activity that offers the National Science Foundation's most prestigious awards in support of junior faculty who exemplify the role of teacher-scholars through outstanding research, excellent education and the integration of education and research within the context of the mission of their organizations. Such activities should build a firm foundation for a lifetime of leadership in integrating education and research. NSF encourages submission of CAREER proposals from junior faculty members at all CAREER-eligible organizations and especially encourages women, members of underrepresented minority groups, and persons with disabilities to apply.

The National Institutes of Health (NIH) Exploratory/Developmental Grant (R21) funding opportunity supports the development of new research activities in categorical program areas. The R21 activity code is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimers disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers.

The purpose of this FOA is to support the development of a Clinician-Scientists Transdisciplinary Aging Research (Clin-STAR) Coordinating Center that will organize activities and provide research resources for clinician-investigators across the United States who are focusing their careers on aging research. This FOA is intended to build upon the substantial investments made by NIA through the GEMSSTAR program and related career development efforts by supporting expanded activities to reach a broader community of clinician-investigators. The specific goals of this initiative are to convey scientific and research knowledge on aging research; foster networking and collaboration between clinician-scientist leaders in aging research and clinician-investigators across specialties who wish to focus on aging research; provide mentoring and career development support for emerging clinician-scientists committed to pursuing aging research in their clinical specialty or discipline; and advance transdisciplinary research projects in aging. Ultimately, the Clin-STAR Coordinating Center is intended to provide a multi-faceted national research platform leading to improved patient-centered care for older adults across specialties and disciplines.

The purpose of this FOA is to support the development of a Clinician-Scientists Transdisciplinary Aging Research (Clin-STAR) Coordinating Center that will organize activities and provide research resources for clinician-investigators across the United States who are focusing their careers on aging research. This FOA is intended to build upon the substantial investments made by NIA through the GEMSSTAR program and related career development efforts by supporting expanded activities to reach a broader community of clinician-investigators. The specific goals of this initiative are to convey scientific and research knowledge on aging research; foster networking and collaboration between clinician-scientist leaders in aging research and clinician-investigators across specialties who wish to focus on aging research; provide mentoring and career development support for emerging clinician-scientists committed to pursuing aging research in their clinical specialty or discipline; and advance transdisciplinary research projects in aging.

The purpose of NIDILRR's Disability and Rehabilitation Research Projects (DRRP), which are funded through the Disability and Rehabilitation Research Projects and Centers Program, is to plan and conduct research, demonstration projects, training, and related activities, including international activities, to develop methods, procedures, and rehabilitation technology that maximize the full inclusion and integration into society, employment, independent living, family support, and economic and social self-sufficiency of individuals with disabilities, especially individuals with the most severe disabilities, and to improve the effectiveness of services authorized under the Rehabilitation Act of 1973, as amended (Rehabilitation Act). Under this particular DRRP priority, applicants must propose a development project that is aimed at improving technology solutions to improve assistive technology to promote independence and community living outcomes of people with disabilities. NIDILRR plans to make three DRRP awards under this grant competition. For this grant competition we are inviting both research applications and development applications. Please note that this forecast is for a Funding Opportunity Announcement for DRRP development projects toward technology solutions to promote independence and community living outcomes of people with disabilities - with a particular emphasis on seniors with disabilities.

This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

The objectives of this new funding opportunity is to provide financial assistance to the territories of American Samoa and Guam to provide, expand and improve the provision of independent living services in each respective territory. Centers for Independent Living (CILs) provide services to assist individuals with disabilities to achieve their maximum potential within their families and communities. CILs are consumer-controlled, community-based, cross-disability, non-residential, private nonprofit agencies. Required core services include:•Information and referrals; •Independent living skills training; •Peer counseling;•Individual and systems advocacy; and •Services that facilitate from nursing homes and other institutions to the community, assistance to individuals at risk of entering institutions, and transition of youth to postsecondary life. The problem that will be addressed is that there is currently no center for independent living (CIL) funded in American Samoa or Guam. The target population is individuals with disabilities. The CIL shall use the funds to provide services to individuals with a range of significant disabilities. The CIL shall (1) facilitate the development and achievement of independent living goals; (2) work to increase the availability and improve the quality of community options for independent living; (3) provide independent living services; (4) conduct activities to increase the capacity of communities within the service area of the CIL to meet the needs of individuals with significant disabilities; and (5) conduct resource development activities to obtain other funding.

The mission of the Administration for Community Living (ACL) Senior Medicare Patrol (SMP) program is to empower and assist Medicare beneficiaries, their families, and caregivers to prevent, detect, and report health care fraud, errors, and abuse. Through outreach, counseling, and education, the SMP program increases awareness and understanding of health care programs to protect Medicare beneficiaries from the economic and health-related consequences associated with Medicare fraud, errors, and abuse. ACL currently provides grant funding to support 53 SMP projects, including grantees in all 50 states, the District of Columbia, Puerto Rico, and Guam. The SMP projects use this funding to provide local outreach, education, and assistance to Medicare beneficiaries through a trained volunteer workforce. SMP projects teach Medicare beneficiaries to protect their Medicare numbers, to detect billing discrepancies on their quarterly Medicare Summary Notice statements, and to report suspicious activity for further investigation. In addition, SMP projects actively disseminate fraud prevention and identification information through the media, outreach campaigns, and community events.

Since 1998, ADDF has provided more than $29 million in funding for early stage clinical drug trials for Alzheimer's disease and related dementias. To help propel novel drugs into the clinic, ADDF also has provided over $6.5 million in support of final preclinical studies required by regulatory agencies for the initiation of clinical research studies. The goal of the foundation's PACT program is to increase the number of innovative treatments tested in humans for Alzheimer's disease and related dementias. To that end, the program will fund clinical trials through Phase 2a of novel drug candidates, including small molecules and biologics (antibodies, oligonucleotides, peptides, gene therapies, cell therapies); proof-of-concept biomarker-based trials in patients for repurposed/repositioned drugs; and regulatory studies for investigational new drug (IND)/clinical trial application preclinical packages that are required before testing novel drugs in human subjects. Proposed molecular targets will be evaluated based on the strength of available evidence linking the target to the disease and demonstrating that modulating its biological activity will improve symptoms or modify disease progression. Current target areas of interest include but are not limited to neuroprotection, inflammation, vascular function, mitochondria and metabolic function, proteostasis, ApoE, epigenetics, and synaptic activity and neurotransmitters.

The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, mechanisms of drug action, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies, or discovery activities such as high throughput screening and hit optimization.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs.

The purpose of NIDILRR's Disability and Rehabilitation Research Projects (DRRP) which are funded through the Disability and Rehabilitation Research Projects and Centers Program, is to plan and conduct research, demonstration projects, training, and related activities, including international activities, to develop methods, procedures, and rehabilitation technology that maximize the full inclusion and integration into society, employment, independent living, family support, and economic and social self-sufficiency of individuals with disabilities, especially individuals with the most severe disabilities, and to improve the effectiveness of services authorized under the Rehabilitation Act of 1973, as amended (Rehabilitation Act). Under this particular DRRP priority, the objective is to improve long-term health outcomes of people with traumatic brain injury (TBI). The grantee will conduct research at the intervention-development stage, to directly inform and shape the development of chronic disease management approaches for meeting the complex and varied health care needs of people with TBI.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this NIA R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce in aging.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIA R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce in aging.

The purpose of this FOA is to provide one year of support for planning activities necessary for initiating a Phase III clinical trial designed to treat patients with Lewy Body Dementias (LBD), which include Dementia with Lewy Bodies and Parkinson's Disease Dementia. Such activities may include identifying trial sites/collaborators, designing trial protocols and procedures, and addressing regulatory approvals.